Initial Beneficial Ownership · 3
OS Therapies Incorporated
OSTXNYSE_AMERICANEQUITYCurrent
Initial Beneficial Ownership
Structured filing — 3
ownership.xml
Filing details
- Report period
- 2026-09-29
- Issuer
- OS Therapies Inc
- Issuer CIK
- 0001795091
- Trading symbol
- OSTX
Reporting owner 1
- Name
- Francis Knuettel II
- Reporting owner CIK
- 0001433316
- Relationship
- Officer
- Officer title
- Chief Financial Officer
- Address
- C/O OS THERAPIES INCORPORATED, 115 PULLMAN CROSSING ROAD, SUITE 103, GRASONVILLE, MD, 21638
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 20,000 | I | By Lara Knuettel Revocable Trust[F1] |
Table key
- I
- Indirect
Footnotes
- F1
- The reporting person is the co-trustee of the Lara Knuettel Revocable Trust and may be deemed to beneficially own the shares of common stock held of record by such trust. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.↩ 1
Remarks
Exhibit 24: Power of Attorney
Signature 1
- Signed
- /s/ Francis Knuettel II
- Date
- 2026-10-05
Filed exhibits
- POWER OF ATTORNEY ↗ea0307732ex-24.htm
Company context
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The Company is the world leader in gene-edited, Listeria-based cancer immunotherapies. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 is designed to target two mutated extracellular epitopes and one mutated intracellular epitope of the HER2 oncogene, requiring only one of these three epitopes to be present in a tumor (or micro-metastasis) to trigger the desired immune response. OST-HER2 has received Orphan Drug Designation (ODD), Fast Track Designation (FTD) and Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and has received ODD, FTD, and Advanced Therapy Medicinal Products (ATMP) from the European Medicines Agency.
Current securities
Recent company filings
- Entry into a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsOct 5, 2026
- S-8 filingSep 21, 2026
- Other EventsSep 10, 2026
- 424B7 filingSep 10, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security HoldersSep 9, 2026